RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+15.08%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$810M
AUM Growth
+$146M
Cap. Flow
+$85.4M
Cap. Flow %
10.54%
Top 10 Hldgs %
36.98%
Holding
72
New
23
Increased
22
Reduced
9
Closed
15
Avg Time Held Equity + Options
0.2 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.2 years
Avg Time Held Equity only
0.2 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.2 years

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$32.8M
2
BMY icon
Bristol-Myers Squibb
BMY
+$20.4M
3
INCY icon
Incyte
INCY
+$19.5M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$18.9M
5
AGN
Allergan Inc
AGN
+$18.8M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$38.7M
2
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$28.8M
3
STJ
St Jude Medical
STJ
+$25.8M
4
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$23.3M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$23.3M

Sector Composition

Rank Sector Weight
1 Healthcare 86.06%
2 Miscellaneous 12.08%
3 Consumer Staples 1.18%
4 Technology 0.55%
5 Communication Services 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GWPH
26
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$15M 1.85%
359,977
+194,957
+118% +$6.17M
2013 Q3
1 quarter
MRK icon
27
CALL
Merck
MRK
$364B
$14.1M 1.74%
296,060
– –
2013 Q2
2 quarters
FRX
28
DELISTED
FOREST LABORATORIES INC
FRX
$13.7M 1.69%
+228,100
New +$11.5M
2013 Q4
0 quarters
PODD icon
29
Insulet
PODD
$9.29B
$13.5M 1.66%
363,036
-235,964
-39% -$8.72M
2013 Q2
2 quarters
CERS icon
30
Cerus
CERS
$451M
$13.3M 1.64%
2,055,574
+3,174
+0.2% +$19.9K
2013 Q2
2 quarters
STJ
31
DELISTED
St Jude Medical
STJ
$13.2M 1.63%
213,164
-444,836
-68% -$25.8M
2013 Q3
1 quarter
NSTG
32
DELISTED
NanoString Technologies, Inc.
NSTG
$13M 1.61%
754,660
+528
+0.1% +$6.54K
2013 Q3
1 quarter
TVTY
33
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$13M 1.6%
846,413
+383,500
+83% +$5.44M
2013 Q3
1 quarter
CMRX icon
34
DELISTED
Chimerix, Inc.
CMRX
$11.3M 1.39%
746,405
+92,700
+14% +$1.48M
2013 Q2
2 quarters
ISEE
35
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$10.2M 1.26%
+316,521
New +$9.39M
2013 Q4
0 quarters
CLDX icon
36
Celldex Therapeutics
CLDX
$2.19B
$9.63M 1.19%
+26,530
New +$10.2M
2013 Q4
0 quarters
WOOF icon
37
DELISTED
VCA Inc.
WOOF
$9.6M 1.18%
306,200
+18,200
+6% +$531K
2013 Q2
2 quarters
TRNX
38
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$9.16M 1.13%
487,577
-80,523
-14% -$1.52M
2013 Q2
2 quarters
ILMN icon
39
Illumina
ILMN
$41B
$9.04M 1.11%
+83,961
New +$7.69M
2013 Q4
0 quarters
SIRO
40
DELISTED
SIRONA DENTAL SYSTEMS INC COM STK
SIRO
$8.73M 1.08%
+124,425
New +$8.65M
2013 Q4
0 quarters
AMRN icon
41
Amarin Corp
AMRN
$245M
$7.86M 0.97%
199,410
+166,925
+514% +$8.64M
2013 Q3
1 quarter
NXTM
42
DELISTED
NxStage Medical Inc.
NXTM
$6.91M 0.85%
+690,770
New +$7.84M
2013 Q4
0 quarters
BSTC
43
DELISTED
BioSpecifics Technologies Corp.
BSTC
$6.2M 0.77%
286,057
-40,595
-12% -$831K
2013 Q2
2 quarters
ELGX
44
DELISTED
Endologix Inc
ELGX
$5.51M 0.68%
+31,573
New +$5.43M
2013 Q4
0 quarters
AMBI icon
45
DELISTED
Ambit Biosciences Corp
AMBI
$5.26M 0.65%
+545,985
New +$7.29M
2013 Q4
0 quarters
XOMA icon
46
DELISTED
Xoma
XOMA
$5.26M 0.65%
+39,059
New +$3.94M
2013 Q4
0 quarters
VCRA
47
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$4.44M 0.55%
284,400
+39,000
+16% +$666K
2013 Q3
1 quarter
FMI
48
DELISTED
Foundation Medicine, Inc.
FMI
$2.62M 0.32%
+110,092
New +$3.08M
2013 Q4
0 quarters
MODN icon
49
DELISTED
MODEL N, INC.
MODN
$1.08M 0.13%
+91,307
New +$853K
2013 Q4
0 quarters
PPH icon
50
VanEck Pharmaceutical ETF
PPH
$1.05B
$345K 0.04%
6,500
– –
2013 Q2
2 quarters
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2013 Portfolio in Review

As of Q4 2013, Redmile Group held 72 positions worth $810M, up 22% from $664M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Redmile Group deployed $85.4M of net new capital in Q4 2013, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Zimmer Biomet: 378,669 shares worth $34.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was St Jude Medical, an estimated $25.8M trimmed.

  • Redmile Group's largest Q4 2013 buy was Zimmer Biomet: 378,669 shares worth $34.3M.
  • Redmile Group added most to Allergan Inc in Q4 2013, an estimated $18.8M increase.
  • Redmile Group's biggest Q4 2013 reduction was St Jude Medical, cutting an estimated $25.8M.
  • Redmile Group fully exited Amgen in Q4 2013, selling an estimated $38.7M.
  • Redmile Group's ten largest holdings make up 37% of its $810M portfolio in Q4 2013.
  • Redmile Group opened 23 new positions and closed 15 in Q4 2013.
  • Redmile Group's portfolio value rose 22% quarter-over-quarter to $810M.

Based on Redmile Group's 13F filing for Q4 2013, filed 14 Feb 2014.